Matching Research Evidence to a Catalog Material

Matching Research Evidence to a Catalog Material

A paper and a catalog page can use the same short name while describing different test articles. One may concern a free base and the other an acetate salt. One may use a native 70-residue protein and the other an 83-residue analogue. One may test an isolated component and the other may sell a multi-component blend.

Before transferring any scientific statement, ask a more basic question: are the source material and the catalog material comparable for the claim being made?

This page provides a practical identity and comparability checklist. It complements the Quality Testing guide but does a different job. Quality Testing explains what methods can and cannot show about a sample. This page decides whether the paper, reference standard, certificate, and catalog record concern the same relevant test article in the first place.

FDA’s Q5E guidance addresses comparability after manufacturing changes for biotechnology and biological products.[2] It is not a rule for research catalog materials. Its narrower value here is methodological: comparability is an evidence-based conclusion about defined materials, not a conclusion created by a shared short name.

Comparability at a glance

No tier allows an animal result, cell signal, or biomarker change to become a human outcome claim.

1. Match the name and authoritative identifier

Start with the preferred scientific name, synonyms, development code, and authoritative identifiers such as a UNII or well-curated structure record. Then inspect the actual definition behind the identifier.

Names are not self-validating. “CJC-1295” is used for DAC and no-DAC active moieties. “IGF-1” can refer to native human IGF-I, mecasermin, LR3, or another analogue. A blend brand may have no standardized scientific definition at all.

FDA’s substance pages also state that a UNII does not imply regulatory review or approval.[8][9] The identifier helps define a substance; it does not prove a catalog lot or its legal status.

2. Match the complete sequence or structure

For a peptide or protein, record the residue sequence in a direction and notation that makes substitutions, D-amino acids, deletions, extensions, cyclization, and conjugates explicit. For a small molecule, use a fully specified structure rather than a pathway label.

One structural change can define a different active moiety:

• CJC-1295 DAC adds an albumin-binding modification that no-DAC CJC-1295 lacks.
• Long R3 IGF-I adds 13 residues and replaces Glu with Arg at the native IGF-I position 3.
• FDA’s 2026 identity review defines TB-500 as a seven-residue N-acetylated fragment; it is not the 43-residue thymosin beta-4 parent.[11]
• GHK is not a complete identity description for a copper complex called GHK-Cu.

If the paper does not report its test article clearly, the evidence boundary should say so.

3. Match stereochemistry

Peptides may include D-amino acids, and small molecules may contain multiple stereocenters. A one-letter sequence written only in capital letters can hide a D-residue. An achiral name can hide a specific enantiomer.

The stereochemical assignment belongs in the identity record. A matching molecular formula or nominal mass does not distinguish all stereoisomers.

4. Match terminal chemistry and conjugation

N-terminal acetylation, C-terminal amidation, side-chain conjugation, metal complexation, cyclization, or other caps can change charge, mass, stability, receptor interaction, and analytical behavior.

This is why “TB-500,” “CJC-1295,” or “kisspeptin” can remain ambiguous even when the general amino-acid family is known. The terminal and side-chain chemistry must match the entity used in the source.

5. Match salt, counterion, and solvation state

A free base, acetate, trifluoroacetate, hydrochloride, sodium salt, hydrate, or solvate may share an active moiety while remaining a different bulk substance or mass basis.

The counterion can affect formula, molecular weight, quantitative calculation, formulation, and analytical method. If a paper or catalog page omits it, state that the active-moiety match is incomplete rather than silently assuming equivalence.

6. Match higher-order structure where relevant

For disulfide-rich peptides and proteins, residue order alone does not establish correct disulfide connectivity, folding, oligomeric state, or aggregation. A mass result may match the expected total while the conformation differs.

FDA’s Q6B framework, within its biotechnology/biological-product scope, separates physicochemical characterization, biological activity, purity, and impurities.[4] It does not apply as a catalog rule here, but it illustrates why one identity measurement cannot answer every structural and functional question.

7. Separate activity units from mass

Milligrams, micrograms, international units, and assay-defined activity units answer different questions. An activity unit depends on a defined assay and reference standard. It cannot be converted to mass by assumption.

A product labeled in activity units needs the assay, standard, calculation, and unit definition. A paper using mass does not automatically match a product using biological units, and the reverse is also true.

8. Define the content and quantity basis

“10 mg” may mean material per vial, active-moiety equivalent, total powder, or total blend. It may or may not include water, counterion, excipients, and other components.

For a blend, record both the per-component amounts and the total. For a salt or hydrate, state the calculation basis. If a URL, title, specification table, and label disagree, stop the evidence transfer until the physical product record is reconciled.

9. Match formulation and physical state

A study may use a defined buffer, vehicle, metal stoichiometry, excipient system, solution, hydrogel, implant, or lyophilized preparation. The catalog material may not.

Formulation can affect recovery, adsorption, aggregation, degradation, and biological exposure. FDA’s Q5C guidance explains why biotechnology and biological products need product-specific stability programs.[3] The scientific principle is relevant even when the guidance’s regulatory scope is not.

10. Link the certificate to the exact lot and sample

A certificate should identify what was tested and how the sample relates to the offered material. Useful fields include:

• product name and SKU;
• lot and sample identifier;
• sampling or chain-of-custody record;
• laboratory identity;
• method and version;
• result, unit, and acceptance criterion;
• report date and revision; and
• reviewer or approver.

FDA’s section 503A page describes a certificate-of-analysis condition for bulk substances used in that compounding context. The eCFR provisions on component identity testing and laboratory records illustrate supplier-document, sample, method, result, calculation, and review controls in drug manufacturing.[5][6][7] Those authorities do not turn a catalog item into a regulated drug. They demonstrate why traceability is part of an interpretable record.

11. Read each analytical result within its limits

No single test proves every material attribute.

• An LC–MS result can support a measured molecular species within the method’s scope. It does not automatically establish purity, content, folding, potency, sterility, endotoxin state, or stability.
• A chromatographic area percentage is method- and detector-dependent. It is not automatically total peptide content by mass.
• A content assay does not establish sequence, stereochemistry, or biological activity.
• A bioassay requires a defined model, endpoint, reference standard, calculation, and unit.
• “Not detected” means below a method’s reported decision point or detection capability, not absolute absence.
• “Pass” is uninterpretable without the result, unit, criterion, method, and lot relationship.

FDA’s Q2(R2) guidance defines validation around fitness for the intended purpose.[1] A method suitable for identity may not be suitable for quantitation, impurities, or stability.

12. Match the study test article and provenance

The paper should report enough about its supplier, batch, preparation, formulation, storage, and analytical checks to understand the test article. Older or exploratory papers often omit some fields.

When provenance is incomplete, do not fill the gap with a vendor specification. Use a visible limitation: the source and catalog material share a proposed active moiety, but direct comparability is not established.

Worked examples

CJC-1295 DAC versus no-DAC

The albumin-binding modification creates a different active moiety. DAC persistence and human pharmacokinetic findings cannot be transferred to no-DAC CJC-1295.

Long R3 IGF-I versus mecasermin

Mecasermin contains the native 70-residue human IGF-I sequence. LR3 is an 83-residue analogue with an extension and substitution. Approval of Increlex does not transfer to LR3.[10]

TB-500 versus thymosin beta-4

FDA’s 2026 identity review defines TB-500 as a seven-residue N-acetylated fragment rather than the 43-residue parent protein.[11] Until the catalog sequence and terminal chemistry are verified, neither literature set should be attached.

GHK versus GHK-Cu

The tripeptide and a copper complex are not a complete identity match. Copper stoichiometry, represented form, formula, and analytical method matter.

Named peptide blends

A brand name does not define component form, ratio, formulation, stability, or lot. Component papers remain Tier 2 background until the exact mixture is directly characterized and studied.

A practical product-link rule

Link a research article to a catalog record only when all five conditions are met:

1. The catalog identity matches the reviewed entity.
2. The amount and units are internally consistent.
3. The form, termini, stereochemistry, higher-order structure, and formulation do not create an unacknowledged mismatch.
4. The lot record is traceable and supports only the claims actually made.
5. The link block states that article evidence does not establish the performance or suitability of the offered material.

If one field remains unresolved, keep the source-led article useful and omit the product link.

Major limitations of identity matching

• A name or acronym may cover multiple active moieties or bulk forms.
• UNII and CAS mappings help define substances but do not prove approval or lot identity.
• Sequence identity does not guarantee stereochemistry, folding, aggregation state, or formulation.
• A certificate applies only within its sample, lot, method, and detection limits.
• Analytical comparability does not expand a cell or animal finding into a human outcome.
• A finished drug’s approval does not transfer to a related research material.
• Some papers do not report enough test-article detail to support a Tier A match.

Frequently asked questions

Is the same common name enough to match a paper to a product?

No. The complete sequence or structure, stereochemistry, termini, form, formulation, quantity basis, and lot evidence may reveal material differences.

Does a matching molecular mass prove identity?

Not by itself. Isomers, stereochemistry, disulfide connectivity, co-eluting species, and some modifications may require additional methods.

Does an FDA UNII mean a material is approved?

No. FDA’s GSRS pages state that UNII availability does not imply regulatory review or approval.[8][9]

Is an acetate salt the same as the free base?

They may share an active moiety, but they are different bulk forms and can have different formulas, mass bases, and specifications. The difference should be stated.

Does HPLC area percentage equal peptide content?

Not automatically. Area percentage depends on the method and detector response and may omit material that is not separated or detected.

Can a certificate from one lot support every future lot?

No. A result supports the tested sample and its traceably linked lot unless a justified sampling and qualification program establishes a broader relationship.

How is this page different from the Quality Testing guide?

This page asks whether the source and catalog material are comparable. The Quality Testing guide explains what individual analytical methods and documents can and cannot establish about a sample.

Primary and official sources

1. FDA/ICH Q2(R2): Validation of Analytical Procedures
2. FDA/ICH Q5E: Comparability of Biotechnological/Biological Products
3. FDA/ICH Q5C: Stability Testing of Biotechnological/Biological Products
4. FDA/ICH Q6B: Specifications for Biotechnological/Biological Products
5. FDA section 503A bulk-substance page
6. eCFR 21 CFR 211.84, component identity testing
7. eCFR 21 CFR 211.194, laboratory records
8. FDA GSRS/UNII record for CJC-1295
9. FDA GSRS/UNII record for Long-(Arg3)IGF-I
10. Current DailyMed label for Increlex/mecasermin
11. FDA 2026 briefing on TB-500-related bulk drug substances